Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 7/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632924 | 0.88 | CRBN (0.41) | CRBNHDAC6HDAC1MAPT | |
| SCHEMBL633440 | 0.85 | CRBN (0.38) | CRBNHDAC6HDAC1 | |
| SCHEMBL632618 | 0.85 | CRBN (0.40) | CRBNHDAC6HDAC1 | |
| SCHEMBL632708 | 0.85 | CRBN (0.39) | CRBNHDAC6HDAC1MAPT | |
| SCHEMBL3340805 | 0.82 | HDAC6 (0.39) | CRBNHDAC6HDAC1MAPT | |
| SCHEMBL633493 | 0.82 | HDAC6 (0.37) | CRBNHDAC6HDAC1LMNA | |
| SCHEMBL632688 | 0.81 | CRBN (0.56) | CRBNHDAC6HDAC1 | |
| SCHEMBL633939 | 0.81 | CRBN (0.36) | CRBNHDAC6HDAC1SMN1; SMN2LMNA | |
| SCHEMBL632680 | 0.80 | GAA (0.44) | CRBNSMN1; SMN2LMNAALDH1A1MAPT | |
| SCHEMBL632684 | 0.80 | HDAC6 (0.39) | CRBNHDAC6HDAC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2093228-B1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TIANJIN HEMAY BIO TECH CO LTD (CN) | 2012-02-22 | — | — | EP | disclosed |
| US-20100152240-A1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | ZHANG HESHENG | 2010-06-17 | — | — | US | disclosed |
| EP-2093228-A1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | Tianjin Hemey Bio-Tech Co., Ltd. (CN) | 2009-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152240-A1 | PYRROLINE-2-ONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF | TNF, IL1B, CYC1 | CRBN 2750/4885HDAC6 2593/4885HDAC1 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.